

Ruth Peters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6148361/publications.pdf>

Version: 2024-02-01

76
papers

4,305
citations

172207

29
h-index

114278

63
g-index

77
all docs

77
docs citations

77
times ranked

6427
citing authors

#	ARTICLE	IF	CITATIONS
1	Committee on High Equality Alzheimer's Disease Studies (CHADS) consensus report. <i>Alzheimer's and Dementia</i> , 2022, 18, 1109-1118.	0.4	3
2	The epidemiology is promising, but the trial evidence is weak. Why pharmacological dementia risk reduction trials haven't lived up to expectations, and where do we go from here?. <i>Alzheimer's and Dementia</i> , 2022, 18, 507-512.	0.4	7
3	Blood pressure change and cognition in childhood and early adulthood: a systematic review. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210851.	1.1	1
4	Diastolic Blood Pressure Variability in Later Life May Be a Key Risk Marker for Cognitive Decline. <i>Hypertension</i> , 2022, 79, 1037-1044.	1.3	9
5	Development of the CogDrisk tool to assess risk factors for dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	1.2	5
6	Exercise interventions to reduce anxiety in mid-life and late-life anxiety disorders and subthreshold anxiety disorder: a systematic review. <i>Therapeutic Advances in Psychopharmacology</i> , 2022, 12, 204512532211049.	1.2	8
7	Toward a theory-based specification of non-pharmacological treatments in aging and dementia: Focused reviews and methodological recommendations. <i>Alzheimer's and Dementia</i> , 2021, 17, 255-270.	0.4	55
8	Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension. <i>Annals of Internal Medicine</i> , 2021, 174, 58-68.	2.0	47
9	Putting Fine Particulate Matter and Dementia in the Wider Context of Noncommunicable Disease: Where are We Now and What Should We Do Next: A Systematic Review. <i>Neuroepidemiology</i> , 2021, 55, 253-265.	1.1	6
10	Zinc Status Alters Alzheimer's Disease Progression through NLRP3-Dependent Inflammation. <i>Journal of Neuroscience</i> , 2021, 41, 3025-3038.	1.7	41
11	Association of sex differences in dementia risk factors with sex differences in memory decline in a population-based cohort spanning 20-76 years. <i>Scientific Reports</i> , 2021, 11, 7710.	1.6	56
12	Intergenerational Programmes bringing together community dwelling non-familial older adults and children: A Systematic Review. <i>Archives of Gerontology and Geriatrics</i> , 2021, 94, 104356.	1.4	24
13	Gender differences in cognitive development in cohorts of young, middle, and older adulthood over 12 years.. <i>Developmental Psychology</i> , 2021, 57, 1403-1410.	1.2	3
14	Association Between Blood Pressure Variability With Dementia and Cognitive Impairment: A Systematic Review and Meta-Analysis. <i>Hypertension</i> , 2021, 78, 1478-1489.	1.3	53
15	Intergenerational Practice in the Community-What Does the Community Think?. <i>Social Sciences</i> , 2021, 10, 374.	0.7	8
16	Development of the First WHO Guidelines for Risk Reduction of Cognitive Decline and Dementia: Lessons Learned and Future Directions. <i>Frontiers in Neurology</i> , 2021, 12, 763573.	1.1	19
17	Evaluation of High Cholesterol and Risk of Dementia and Cognitive Decline in Older Adults Using Individual Patient Meta-Analysis. <i>Dementia and Geriatric Cognitive Disorders</i> , 2021, 50, 318-325.	0.7	15
18	Frailty in Indigenous Populations: A Scoping Review. <i>Frontiers in Public Health</i> , 2021, 9, 785460.	1.3	4

#	ARTICLE	IF	CITATIONS
19	Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in-depth exploration of seven established risk factors. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12202.	1.8	12
20	Dementia Risk Scores and Their Role in the Implementation of Risk Reduction Guidelines. <i>Frontiers in Neurology</i> , 2021, 12, 765454.	1.1	18
21	Incidence and prevalence of coexistent retinal diseases and cognitive impairment or dementia: A systematic review. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
22	Evaluation of blood pressure and cognitive function using individual participant data meta-analysis: The LifeCourse Blood Pressure Cognition (LCBP&COG) study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
23	Left ventricular hypertrophy and incident cognitive impairment in elderly hypertensive patients: Hypertension in the Very Elderly Trial. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
24	Trajectory of blood pressure, body mass index, cholesterol and incident dementia: systematic review. <i>British Journal of Psychiatry</i> , 2020, 216, 16-28.	1.7	52
25	Advancing dementia prevention through effective blood pressure control. <i>Lancet Neurology</i> , The, 2020, 19, 25-27.	4.9	9
26	What does (low) education mean in terms of dementia risk? A systematic review and meta-analysis highlighting inconsistency in measuring and operationalising education. <i>SSM - Population Health</i> , 2020, 12, 100654.	1.3	37
27	Anti-inflammatories in Alzheimer's disease: potential therapy or spurious correlate?. <i>Brain Communications</i> , 2020, 2, fcaa109.	1.5	52
28	Future Directions for Dementia Risk Reduction and Prevention Research: An International Research Network on Dementia Prevention Consensus. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 3-12.	1.2	22
29	Higher diastolic blood pressure aged 40&44 is associated with declining cognition and increasing white matter lesions over 8&12 year follow up.. <i>Alzheimer's and Dementia</i> , 2020, 16, e045569.	0.4	1
30	Subjective memory decline and neuropsychological performance. <i>Alzheimer's and Dementia</i> , 2020, 16, e045656.	0.4	0
31	Investigation of antihypertensive class, dementia, and cognitive decline. <i>Neurology</i> , 2020, 94, e267-e281.	1.5	78
32	Abstract MP36: Effects Of Intensive Blood Pressure Treatment On Orthostatic Hypotension: An Individual-level Meta-analysis. <i>Hypertension</i> , 2020, 76, .	1.3	1
33	A Systematic Review of Meta-Analyses that Evaluate Risk Factors for Dementia to Evaluate the Quantity, Quality, and Global Representativeness of Evidence. <i>Journal of Alzheimer's Disease</i> , 2019, 70, S165-S186.	1.2	98
34	Common risk factors for major noncommunicable disease, a systematic overview of reviews and commentary: the implied potential for targeted risk reduction. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231988039.	1.1	98
35	Combining modifiable risk factors and risk of dementia: a systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e022846.	0.8	138
36	Blood pressure and dementia. <i>Neurology</i> , 2019, 92, 1017-1018.	1.5	51

#	ARTICLE	IF	CITATIONS
37	No clear relationship between antihypertensive class and cognitive function over 12 months in a cohort study of community-dwelling adults aged 80 and over. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231882084.	1.1	1
38	Greater cognitive decline relative to normal ageing occurs at least 10 years prior to clinical dementia diagnosis. <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 79-79.	1.7	0
39	Effect of SSRI and calcium channel blockers on depression symptoms and cognitive function in elderly persons treated for hypertension: three city cohort study. <i>International Psychogeriatrics</i> , 2018, 30, 1345-1354.	0.6	14
40	P3ɍ: HIGH URIC ACID ASSOCIATED WITH REDUCED RISK OF COGNITIVE DECLINE IN HYPERTENSIVE OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1352.	0.4	0
41	More evidence is needed. Iron, incident cognitive decline and dementia: a systematic review. <i>Therapeutic Advances in Chronic Disease</i> , 2018, 9, 241-256.	1.1	14
42	Updating the Evidence on the Association between Serum Cholesterol and Risk ofäLate-Life Dementia: Review andäMeta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 215-228.	1.2	226
43	Joining forces to prevent dementia: The International Research Network On Dementia Prevention (IRNDP). <i>International Psychogeriatrics</i> , 2017, 29, 1757-1760.	0.6	28
44	Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5. <i>JAMA Internal Medicine</i> , 2017, 177, 1498.	2.6	158
45	Antihypertensive treatment decreases arterial stiffness at night but not during the day. Results from the Hypertension in the Very Elderly Trial. <i>Blood Pressure</i> , 2017, 26, 109-114.	0.7	0
46	Type 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A Pooled Analysis of 2.3 Million People Comprising More Than 100,000 Cases of Dementia. <i>Diabetes Care</i> , 2016, 39, 300-307.	4.3	450
47	Literature review of visual representation of the results of benefitÉc;risk assessments of medicinal products. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 238-250.	0.9	22
48	Left ventricular hypertrophy is a predictor of cardiovascular events in elderly hypertensive patients. <i>Journal of Hypertension</i> , 2016, 34, 2280-2286.	0.3	29
49	Relationship Between Antihypertensive Medications and Cognitive Impairment: Part I. Review of Human Studies and Clinical Trials. <i>Current Hypertension Reports</i> , 2016, 18, 67.	1.5	27
50	Relationship Between Antihypertensive Medications and Cognitive Impairment: Part II. Review of Physiology and Animal Studies. <i>Current Hypertension Reports</i> , 2016, 18, 66.	1.5	17
51	The risk of overweight/obesity in mid-life and late life for the development of dementia: a systematic review and meta-analysis of longitudinal studies. <i>Age and Ageing</i> , 2016, 45, 14-21.	0.7	319
52	Antihypertensive drug use and risk of cognitive decline in the very old. <i>Journal of Hypertension</i> , 2015, 33, 2156-2164.	0.3	22
53	The clock drawing test, mortality, incident cardiovascular events and dementia. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 416-421.	1.3	0
54	Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 160-169.	1.1	19

#	ARTICLE	IF	CITATIONS
55	No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the Hypertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. <i>BMC Medicine</i> , 2015, 13, 78.	2.3	244
56	Is air pollution associated with increased risk of cognitive decline? A systematic review. <i>Age and Ageing</i> , 2015, 44, 755-760.	0.7	47
57	Limitations, including the misclassification of former drinkers. <i>Addiction Research and Theory</i> , 2013, 21, 196-197.	1.2	1
58	Modelling Cognitive Decline in the Hypertension in the Very Elderly Trial [HYVET] and Proposed Risk Tables for Population Use. <i>PLoS ONE</i> , 2010, 5, e11775.	1.1	15
59	The effect of treatment based on a diuretic (indapamide) & ACE inhibitor (perindopril) on fractures in the Hypertension in the Very Elderly Trial (HYVET). <i>Age and Ageing</i> , 2010, 39, 609-616.	0.7	77
60	Literature Review of the Clock Drawing Test as a Tool for Cognitive Screening. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 201-213.	0.7	177
61	Antihypertensive Treatment After Diagnosis of Alzheimer's Disease. <i>American Journal of Hypertension</i> , 2009, 22, 1031-1031.	1.0	1
62	Sociodemographic and lifestyle risk factors for incident dementia and cognitive decline in the HYVET. <i>Age and Ageing</i> , 2009, 38, 521-527.	0.7	32
63	The prevention of dementia. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 452-458.	1.3	43
64	Hypertension, dementia, and antihypertensive treatment: Implications for the very elderly. <i>Current Hypertension Reports</i> , 2009, 11, 277-282.	1.5	31
65	Baseline characteristics of participants in the Hypertension in the Very Elderly Trial (HYVET). <i>Blood Pressure</i> , 2009, 18, 17-22.	0.7	6
66	Vascular risk factors and cognitive function among 3763 participants in the Hypertension in the Very Elderly Trial (HYVET): a cross-sectional analysis. <i>International Psychogeriatrics</i> , 2009, 21, 359.	0.6	14
67	Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. <i>Lancet Neurology</i> , The, 2008, 7, 683-689.	4.9	659
68	Alcohol, dementia and cognitive decline in the elderly: a systematic review. <i>Age and Ageing</i> , 2008, 37, 505-512.	0.7	317
69	Predictive Value of the Clock Drawing Test. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 351-355.	0.7	35
70	Hypertension in the very elderly. <i>Aging Health</i> , 2007, 3, 517-525.	0.3	3
71	Fracture risk and the use of a diuretic (indapamide sr) & perindopril: a substudy of the Hypertension in the Very Elderly Trial (HYVET). <i>Trials</i> , 2006, 7, 33.	0.7	17
72	Validity of the Clock-Drawing Test as a Screening Tool for Cognitive Impairment in the Elderly. <i>American Journal of Epidemiology</i> , 2004, 160, 797-807.	1.6	112

#	ARTICLE	IF	CITATIONS
73	Does additional feeding support provided by health care assistants improve nutritional status and outcome in acutely ill older in-patients?â€”a randomised control trial. <i>Clinical Nutrition</i> , 2004, 23, 69-77.	2.3	97
74	THE ASSESSMENT OF QUALITY OF LIFE IN THE HYPERTENSION IN THE VERY ELDERLY (HYVET) TRIAL. <i>Journal of Hypertension</i> , 2004, 22, S96.	0.3	0
75	CHANGE IN COGNITIVE FUNCTION WITHIN THE FIRST YEAR OF ENTERING THE HYPERTENSION IN THE VERY ELDERLY TRIAL (HYVET). <i>Journal of Hypertension</i> , 2004, 22, S54-S55.	0.3	0
76	No clear associations between subjective memory concerns and subsequent change in cognitive function: the PATH through life study. <i>European Journal of Ageing</i> , 0, , 1.	1.2	0